Novo Nordisk A/S (NASDAQ: NVO) beats Q2 2026 adjusted EPS consensus of approx. $0.82 per ADS on August 5, 2026
Hit
✦ AI-generated prediction
Published on 12. July 2026
·
Predicted for 5. August 2026
·
Based on: Historical Cycle
Novo Nordisk reports Q2 2026 on August 5. The ADS EPS consensus stands at approximately $0.82 per TipRanks. GLP-1 demand for semaglutide (Ozempic/Wegovy) remains structurally strong; Novo benefits from global capacity expansion and growing reimbursements in Europe and the US. Competitive pressure from Eli Lilly (tirzepatide) is priced in. Novo has beaten EPS consensus in each of the last four quarters. Beat probability: 71%. Currency risk (DKK/USD, EUR/USD) could dampen USD ADS translation. No Polymarket market available.
Data basis for this prediction
- TipRanks: NVO Q2-2026-EPS-Konsens ~0,82 USD ADS, Ergebnisdatum 05.08.2026
- Trading Economics EUR/USD: 1,1416 am 12.07.2026 (Währungsrisiko DKK-Konversion beachten)
- Novo Nordisk IR: Semaglutid-Kapazitätsausbaupläne 2025–2026; Ozempic/Wegovy globale Marktdaten
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Hit
Novo Nordisk übertraf am 5. August 2026 den bereinigten EPS-Konsens deutlich: Tatsächliches adjustiertes EPS: 0,9527 USD je ADS vs. Konsens 0,7815 USD – ein Beat von ca. +22 %. Auch der Umsatz (12,1 Mrd. USD vs. 10,94 Mrd. erwartet) übertraf die Erwartungen. Treiber waren weiterhin starke GLP-1-Nachfrage (Ozempic/Wegovy) sowie ein Rekordstart der oralen Wegovy-Pille in den USA. Quellen: Investing.com Earnings Call Transcript (https://www.investing.com/news/transcripts/earnings-call-transcript-novo-nordisk-beats-q2-2026-estimates-shares-rise-premarket-93CH-4837532), MarketBeat (https://www.marketbeat.com/earnings/reports/2026-8-5-novo-nordisk-as-stock/), Globe and Mail (https://www.theglobeandmail.com/investing/markets/stocks/NVO-N/pressreleases/3670985/novo-nordisk-lifts-2026-outlook-after-strong-q2-adjusted-results/).
📈 Economy
✦ AI
The DAX closed at 25,562 points on September 9, 2026. A gain of +1.7% is required by month-end. Headwinds: ECB rate hike to 2.50% (September 10), 53% FOMC hike probability (September 16), persistently high oil prices (~$101/barrel Brent) weigh on energy-intensive DAX heavyweights. Tailwinds: strong SAP cloud growth expected, robust US demand, EUR/USD at 1.1644 benefits exporters. Implied 30-day volatility (VDAX): ~16%, corresponding to a σ range of roughly ±5.5% by month-end — the 26,000 level falls within the central distribution.
📈 Economy
✦ AI
Polymarket shows a 53% probability for a 25 basis point hike as of September 10, 2026. US Core CPI August 2026 (release September 11) is expected by market consensus to be above 3.0% YoY. The ECB raised its deposit rate by 25 bps to 2.50% on September 10, 2026 – an inflation-fighting signal that provides cover for the Fed. Against a hike: a mild slowdown in US industrial output. CME FedWatch also shows ~53% probability for a hike.
📈 Economy
✦ AI
Bitcoin at $78,136 (September 9, 2026). Kalshi markets assign ~83% probability of BTC touching $100,000 at any point in 2026. Polymarket gives BTC 68% odds to close above $90,000 by year-end. A year-end close above $100,000 (not just a touch) is more demanding: median year-end contract estimates imply ~$81,000. Arguments for >$100k close: historical Q4 seasonality (+49% in Q4 2024, +56% in Q4 2023), ETF inflows, institutional demand. Headwinds: active Fed hiking cycle (~3.75% current funds rate), 10yr yield at 4.86%.